Tickertape - Financial freedom begins here

The transaction is subject to receipt of the necessary regulatory and customary approvals under the definitive agreements. 'Upon consummation of the transaction, MCCPL will become a wholly-owned subsidiary of the company,' JSW Energy said in a statement. MCCPL owns and operates a 300 MW thermal power plant at Korba, Chhattisgarh. The plant has a long term power purchase agreement (PPA) of 195 MW (net) with Rajasthan discoms, routed through PTC India, with a residual PPA life of nearly 14 years. In addition, the plant provides 5% power at variable cost to the Chhattisgarh discom, while the balance 64 MW capacity is sold in the merchant market. Coal is secured through a long-term fuel supply agreement with SECL, and linkage under the SHAKTI scheme. The transaction values MCCPL at an Enterprise Value of approximately Rs 1,410 crore, subject to customary closing adjustments as per the definitive agreements. The acquired asset's estimated FY26 EBITDA stood at Rs 279 crore. This operating asset is EBITDA and PAT-accretive, while also reducing the company's net leverage and strengthening overall balance sheet resilience. Beyond the immediate financial benefits, the asset offers potential upside through optimisation of logistics and O&M costs. Its proximity to JSW Energy's Mahanadi thermal plant further unlocks operational synergies, strengthening the Company's regional thermal footprint. JSW Energy currently operates an installed thermal capacity of 5,658 MW, with a further 3,200 MW under construction at its Salboni Thermal Power Plant and a pipeline of 1,800 MW for brownfield expansion at Mahanadi. This operating asset acquisition further strengthens the Company's installed thermal portfolio. Post closure, the Company's total installed and locked-in thermal capacity will reach 5,958 MW and 10,958 MW respectively. Sharad Mahendra, joint managing director and CEO, of JSW Energy, said: This acquisition reflects our disciplined 'Build vs. Buy' approach, where we pursue calibrated value accretive inorganic opportunities. MCCPL has an operating asset that is earnings accretive from day one, strengthening both our thermal portfolio and our cash flows. As we fortify our thermal generation capacity, we remain proud to play our part in powering India's growth and supporting the nation's energy security. This transaction is another step in building a balanced, resilient portfolio that delivers sustainable returns while meeting the country's rising energy needs. JSW Energy is a private sector power producer in India and part of JSW group. It has established its presence across the value chains of power sector with diversified assets in power generation and transmission. The company had reported a 38.36% jump in consolidated net profit to Rs 573.53 crore in Q4 FY26, compared with Rs 414.51 crore in Q4 FY25. However, revenue from operations jumped 41.04% YoY to Rs 4,498.58 crore for the quarter ended 31 March 2026. The scrip had advanced 1.37% to end at Rs 559.60 on the BSE on Friday. Powered by Capital Market - Live

Diamond Power Infrastructure will hold a meeting of the Board of Directors of the Company on 18 June 2026.

Samyak International announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 9 July 2026.

India Shelter Finance Corp. announced that the 28th Annual General Meeting(AGM) of the company will be held on 16 July 2026.

Alkali Metals announced that the 58th Annual General Meeting(AGM) of the company will be held on 21 August 2026.

The pharmaceutical major has collaborated with MSN Laboratories (MSN), a leading pharmaceutical company in India, on this product. Dr. Reddy's holds the exclusive marketing rights for the product in the United States. MSN is responsible for the development and manufacturing of the product. Bosutinib Tablets was a first-to-file product and is eligible for 180-days of generic drug exclusivity for this strength, in the U.S. The Bosulif brand had U.S. sales of approximately $253.8 million for the latest 12-month period ended April 2026, according to IQVIA National Sales Perspectives data. Milan Kalawadia, CEO- North America, Dr. Reddy's Laboratories, Inc. said: This launch highlights our commitment to leading with timely market entry for high-priority therapies while broadening access for both patients and healthcare providers. With this launch, we remain focused on strengthening our oncology portfolio and partnering across the healthcare system to ensure that critical treatments are both accessible and affordable. Hyderabad-based Dr. Reddy's Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. The company had reported a 86.14% decline in consolidated net profit to Rs 220.9 crore on 11.51% drop in revenue from operations to Rs 7,546.4 crore in Q4 FY26 over Q4 FY25. The scrip shed 0.09% to end at Rs 1273.90 on the BSE on Friday. Powered by Capital Market - Live

Net loss of Sanchay Finvest reported to Rs 0.42 crore in the quarter ended March 2026 as against net profit of Rs 0.02 crore during the previous quarter ended March 2025. Sales reported to Rs 0.01 crore in the quarter ended March 2026 as against Rs -0.12 crore during the previous quarter ended March 2025. For the full year,net loss reported to Rs 1.41 crore in the year ended March 2026 as against net loss of Rs 0.32 crore during the previous year ended March 2025. Sales reported to Rs -0.02 crore in the year ended March 2026 as against Rs 0.26 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales0.01-0.12 LP -0.020.26 PL OPM %-1800.00166.67 -3600.00-96.15 - PBDT-0.170.01 PL -0.67-0.17 -294 PBT-0.170 0 -0.69-0.21 -229 NP-0.420.02 PL -1.41-0.32 -341 Powered by Capital Market - Live

Each warrant is convertible into one equity share within 18 months from the date of allotment. Of the total proposed issuance, 64.19 lakh warrants aggregating Rs 500 crore will be allotted to promoters Dr. Abhinay Bollineni and Mr. Advik Bollineni, while 12.84 lakh warrants aggregating Rs 100 crore will be allotted to promoter-group entity Bharas Ventures LLP. The proposal remains subject to shareholder approval and other regulatory clearances. The company has also scheduled an extra-ordinary general meeting (EGM) for 09 July 2026 to seek shareholder consent for the same. Assuming 100% conversion of warrants, shareholding of Dr. Abhinay Bollineni will rise to 0.84% from 0.06% currently, and that of Adwik Bollineni will climb to 0.80% from 0.01%. Bharas Ventures LLP will own 0.31% stake in the company post warrant conversion. Bharas Ventures is a limited liability partnership between the company's two promoters, viz., Dr. Bhaskara Rao Bollineni and Ms. Rajyasri Bollineni. Headquartered in Hyderabad, Krishna Institute of Medical Sciences (KIMS Hospitals) is one of the largest corporate healthcare groups in Telangana and Andhra Pradesh, providing multi-disciplinary integrated healthcare services, with a focus on tertiary and quaternary healthcare at affordable cost. The company's consolidated net profit declined 58.25% to Rs 42.50 crore despite a 34.85% increase in revenue to Rs 1,074.60 crore in Q4 FY26 over Q4 FY25. The scrip fell 2.88% to end at Rs 787.10 on the BSE on Friday. Powered by Capital Market - Live

According to the company's regulatory filing, Chhabra's resignation will be effective from the close of business hours on 7 July 2026. Campus Activewear stated that the CFO tendered his resignation citing personal reasons and will cease to be associated with the company upon completion of his notice period. Campus Activewear is a leading Indian sports and athleisure footwear brand engaged primarily in the design, manufacturing, and distribution of footwear across retail, wholesale, and online channels, with a small complementary presence in accessories. The company's net profit jumped 26.01% to Rs 44.14 crore on a 12.3% increase in revenue from operations to Rs 455.63 crore in Q4 FY26 over Q4 FY25. The counter advanced 2.78% closed at Rs 238.30 on the BSE on Friday. Powered by Capital Market - Live

Lloyds Enterprises announced that the 40th Annual General Meeting(AGM) of the company will be held on 9 July 2026.